Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
暂无分享,去创建一个
Kimberly Smith | M. Aboud | R. Kaplan | M. Losso | C. Brites | P. Chetchotisakd | Y. Punekar | Fujie Zhang | J. Lombaard | M. Underwood | J. Hidalgo | Dannae Brown | Elmira Mamedova | J. Sievers | J. Hopking | M. Nascimento | M. Gartland | Jörg Sievers